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Abstract Sialidosis is a lysosomal storage disease caused
by the deficiency of alpha-N-acetyl neuraminidase-1
(NEU1). Sialidosis is classified into two main clinical
variants: Type I, the milder form of the disease, and Type
II, which can in turn be subdivided into three forms: con-
genital, infantile and juvenile. We report herein the clini-
cal, biochemical and molecular characterisation of two
patients with Type II sialidosis exhibiting the congenital
(P1) and infantile forms (P2). We also review clinical data
on the rare Type II forms of sialidosis in the hope of
improving understanding of the disorder and facilitating its
diagnosis. The genetic characterization of the two patients
showed one known [c. 679G [ A (p.G227R)] NEU1
missense mutation (detected in P2), and the new
c.807 ? 1G [ A splicing defect (detected in P1), a genetic
lesion that is extremely rare in this disease. Interestingly,
P2 presented an extremely elevated level of chitotriosidase
in plasma. This is the first pathological detection of chi-
totriosidase in sialidosis patients.
Introduction
Patients with Type II sialidosis develop progressive
mucopolysaccharidosis-like features, including coarse
facies, visceromegaly, dysostosis multiplex, and severe
mental retardation.
To our knowledge, only one study mentions the assay of
chitotriosidase in one sialidosis plasma sample that did not
exhibit an increase in enzyme activity [9]. Chitotriosidase
is markedly secreted by activated macrophages in various
conditions involving inflammatory processes, atheroscle-
rosis and hematological disorders. Increases in this
enzyme’s activity have also been detected in plasma
specimens from some patients with lysosomal storage
disorders [9, 10, 17].
Patients
The main clinical manifestations of P1 and P2 and of
previously reported patients with Type II sialidosis are
reported in Tables 1 and 2. The infantile and the juvenile
phenotype of Type II sialidosis are presented together in
Table 2.
P1 and P2 presented normal beta-galactosidase activity,
and, respectively no residual NEU1 activity and 0.31 nmol/
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mg/h (vn = 131.5 ± 65.7) NEU1 activity, detected in
fibroblasts.
P1 exhibits the congenital form of the disease with
trombocytopenia and pulmonary interstitial thickening. P2
presented with psychomotor delay, congenital cataract and
sensorineural hearing loss in the first year. He went on to
develop dysostosis multiplex with regression of psycho-
motor development, cherry red spot and epilepsy in the
early years of childhood. He also presented extremely
elevated chitotriosidase levels (12,600 nmol/ml/h vn
25.75 ± 17), about 250 times the normal level.
Both congenital and infantile/juvenile phenotypes,
present course facies, psychomotor delay, organomegaly
and ocular manifestations. Clinical evidence on Type II
patients reveals the distinctive features of congenital
sialidosis to be hydrops, ascites, oedema, skin telangiec-
tases and petechie, and hydrocephalus (only one case) [5].
A private and atypical sign of the longer surviving phe-
notype is microcephaly, found in a 12 year old patient
[3].
Myoclonic seizures are well documented in Type I
sialidosis [31], but it should be noted that 8/17 Type II
infantile/juvenile and 3/28 patients with the congenital
form exhibited epileptic seizures or myoclonus (Tables 1,
2). Renal involvement is present in only a few cases: one
belonging to the hydropic form and four to the infantile/
juvenile phenotypes.
Molecular analysis
Molecular analysis identified one known [c.679G [ A
(p.G227R)] missense mutation [16], and the new splicing
transition c.807 ? 1G [ A. Both mutations were
homozygous.
The splicing defect gives rise to at least one aberrant
mRNA transcript containing the genetic sequence of intron
4. This insertion results in the premature UGA stop codon
starting at position c.807 ? 13.
In the proximal promoter of P2’s chitotriosidase gene
(CHIT1) no mutations or SNPs were observed.
Screening of the 24 bp duplication in exon 10 of CHIT1
(leading to a complete but non pathological enzyme defect)
showed normal PCR products in both patients.
Discussion
Clinical onset, severity of symptoms and course differ in
the congenital and infantile/juvenile subgroups. Ascites
and oedema are clearly related to the more severe con-
genital group of the disease. In longer surviving pheno-
types oedema was present in only one infantile patient [26].
On the other hand some clinical manifestations such as
ataxia, anorexia and hearing loss, characteristic of the late-
onset Type II subgroups, are likely to become increasingly
severe as patients age.
The evaluation of chitotriosidase was useful in the dif-
ferential diagnosis of the disease in P2. The patient was
first hospitalized after epileptic seizures at 1 year of age
and was initially suspected of suffering from Gaucher
disease due to the high level of plasma chitotriosidase. An
increased expression of P2’ s CHIT1 was excluded by
amplifying and sequencing its promoter region. Thus,
plasma chitotriosidase could be a supplementary bio-
chemical marker that might be worth investigating in such
patients.
Molecular characterization of P1’s NEU1 gene showed
the new allelic variant c.807 ? 1G [ A. To our knowledge
only one additional splicing defect has been reported [22].
The known c. 679G [ A (p.G227R) mutation has a
relatively high occurrence and our findings support the
hypothesis of an European ancestry [3].
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